KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy

Eugen Trinka,Benjamin Duncan,Wim Van Paesschen,Bernd Pohlmann-Eden,Petr Hon,Jacqueline Marovac,Mark Newton,Yngve Hallström,Sonja Buyle,Gian Carlo Muscas,Heinz-Joachim Meencke,Reetta Kälviäinen,Anthony G Marson,Philip E Smith

doi:10.1136/jnnp-2011-300376

Abstract

ObjectiveTo compare the effectiveness of levetiracetam (LEV) with extended-release sodium valproate (VPA-ER) and controlled-release carbamazepine (CBZ-CR) as monotherapy in patients with newly diagnosed epilepsy.MethodsThis unblinded, randomised, 52-week superiority trial (NCT00175903)...

Full Text